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ABSTRACT
Non-genotoxic reactivation of the p53 pathway by MDM2-p53 binding antagonists 
is an attractive treatment strategy for wild-type TP53 cancers. To determine how 
resistance to MDM2/p53 binding antagonists might develop, SJSA-1 and NGP cells 
were exposed to growth inhibitory concentrations of chemically distinct MDM2 
inhibitors, Nutlin-3 and MI-63, and clonal resistant cell lines generated. The p53 
mediated responses of parental and resistant cell lines were compared. In contrast 
to the parental cell lines, p53 activation by Nutlin-3, MI-63 or ionizing radiation was 
not observed in either the SJSA-1 or the NGP derived cell lines. An identical TP53 
mutation was subsequently identified in both of the SJSA-1 resistant lines, whilst one 
out of three identified mutations was common to both NGP derived lines. Mutation 
specific PCR revealed these mutations were present in parental SJSA-1 and NGP 
cell populations at a low frequency. Despite cross-resistance to a broad panel of 
MDM2/p53 binding antagonists, these MDM2-amplified and TP53 mutant cell lines 
remained sensitive to ionizing radiation (IR). These results indicate that MDM2/
p53 binding antagonists will select for p53 mutations present in tumours at a low 
frequency at diagnosis, leading to resistance, but such tumours may nevertheless 
remain responsive to alternative therapies, including IR.
INTRODUCTION
The p53 tumour suppressor protein, encoded by the 
TP53 gene, is post-translationally activated in response to a 
diverse range of cellular stresses and can lead to cell cycle 
arrest and apoptosis through both transcription dependent 
and independent mechanisms [1]. This process is tightly 
regulated by an autoregulatory feedback loop involving 
a direct protein-protein binding interaction between p53 
and the product of the MDM2 oncogene, which is also 
transcriptionally driven by p53. Once bound to p53, MDM2 
inhibits p53 dependent transcription and also ubiquitinates 
the p53 protein to target it for nuclear export and proteasomal 
degradation. The importance of the p53 pathway in 
determining the appropriate response to such stresses is 
reflected by the high frequency with which p53 pathway 
abnormalities are observed in adult sporadic malignancies. 
In the approximately 50% of tumours that have a wild-
type TP53 gene upon diagnosis, other aberrations in the 
regulatory networks which control p53 activation are often 
observed [2–4] including amplification of the MDM2 
oncogene. Reactivation of wild-type p53 by small selective 
antagonists of the MDM2/p53 binding interaction is an 
attractive treatment strategy in these tumours [5].
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The cis-imidazoline Nutlin-3 and the spiro-oxindole 
MI-63 are two compounds that have been developed as 
MDM2/p53 binding antagonists and shown to activate 
wild-type p53 both in vitro and in vivo [6, 7]. Studies with 
these compounds have supported the concept that non-
genotoxic p53 activation might represent an alternative 
to current genotoxic chemotherapy in malignancies 
expressing wild-type TP53. Nutlin-3 and MI-63 increase 
the expression of p53 transcriptional target genes, such as 
those encoding p21WAF1 and MDM2, and induce cell cycle 
arrest and apoptosis in a p53 dependent manner. Both 
classes of antagonists have also been demonstrated to have 
in vivo activity [6, 8]. The first of this class of compound, 
RG7112 (Roche) has recently completed phase I clinical 
trials [9], whilst others, such as the spirooxindoles and 
the isoindolinones, which are being developed in this 
laboratory [10], are in late stage pre-clinical development.
Resistance to chemotherapy is associated with 
poor clinical responses and may either be due to intrinsic 
properties of the tumour or arise during the course of 
treatment. During the pre-clinical development of a novel 
class of anti-cancer agents it is useful to anticipate the 
mechanisms by which tumours may develop resistance 
to these agents. Many chemotherapeutic regimes induce 
multi-drug resistance by increasing the expression 
of export pumps such as p-glycoprotein (P-gp) and 
multi-drug resistance protein (MRP-1) in tumours and 
consequently the sensitivity of these tumours to a diverse 
range of chemotherapeutic agents is reduced [11]. 
Alternatively, treatment may induce or select for changes 
in the target that lead to resistance.
Intrinsic properties of tumours which may determine 
their initial sensitivity to MDM2/p53 binding antagonists 
have been extensively investigated in cell culture models 
and, as predicted from their mechanism of action, have 
confirmed the importance of wild-type p53. MDMX levels 
have also been proposed to play a role in determining the 
intrinsic sensitivity of cell lines to MDM2/p53 binding 
antagonists. MDMX is critically involved in the negative 
regulation of p53 alongside MDM2 and high levels of 
MDMX expression have been reported to correlate with 
reduced responses to Nutlin-3 [12, 13]. However, this 
is likely to be cell line specific as other studies have not 
identified MDMX as a major determinant of sensitivity 
to MDM2-p53 binding antagonists [14–16]. Established 
cell culture models have been used to investigate the 
susceptibility of Nutlin-3 to multi-drug resistance and the 
overexpression of P-gp was found to have little overall 
effect on sensitivity to Nutlin-3 as a single agent [17]. 
However, Nutlin-3 was found to be a P-gp substrate, and 
in this way inhibit P-gp mediated efflux of other drugs 
[18].
Studies, including those described here, have started 
to address how resistance to this class of compounds 
might develop during the course of treatment. Repeat 
exposure to Nutlin-3 was recently reported to induce p53 
mutations in a cell culture models [19, 20]. Nutlin-3 has 
also been reported to increase markers of genotoxicity 
such as ɤ-H2AX and ATM autophosphorylation [21]. 
The generation of p53 mutations by Nutlin-3 during 
the development of resistance observed in these studies 
may be a specific response to Nutlin-3 mediated DNA 
damage rather than a general response to non-genotoxic 
reactivation of p53 by MDM2/p53 binding antagonists.
In this study, we investigated the mechanism by 
which resistance to MDM2/p53 binding antagonists may 
develop in more detail, using two chemically distinct 
classes of inhibitors. Two MDM2-amplified cell lines 
have been selected for resistance to growth inhibitory 
concentrations of Nutlin-3 and MI-63, and following the 
selection of resistant clones the mechanism of resistance 
has been characterised, including the response of the 
selected cells to ionizing radiation.
RESULTS
Cell lines with resistance to MDM2/p53 binding 
antagonists were generated by continuously exposing 
SJSA-1 osteosarcoma cells and NGP neuroblastoma cells 
to either Nutlin-3 or MI-63. MI-63 was used at a lower 
concentration than Nutlin-3 owing to its greater potency 
[7]. The SJSA-1 and NGP parental cell lines both have 
an amplified MDM2 gene and express wildtype TP53. 
They are therefore a good model for the development 
of clinical resistance to this class of agents. S_M6R1 
and S_N40R2 cells were developed from SJSA-1 cells 
following exposure to a final concentration of 6 μM MI-
63 or 40 μM Nutlin-3 whilst N_M5R1 and N_N20R1 
cells were developed from NGP cells following exposure 
to MI-63 or Nutlin-3 at final concentrations of 5 μM or 
20 μM respectively (Figure 1A). The resistant sub-clones 
then underwent STR profiling to confirm that the selected 
daughter sub-clones were derived from their parental cell 
lines (Supplementary Figure S1).
Cross-resistance to growth inhibition by different 
classes of MDM2-p53 binding antagonist
Resistance was confirmed by comparing the 
concentrations of MI-63 and Nutlin-3 required to inhibit 
the growth of these cell lines and parental cell lines by 
50%. Following 72 hours continuous exposure to the 
antagonists, the cell lines generated were found to be 
resistant to both antagonists. In comparison to the parental 
SJSA-1 cells, S_M6R1 and S_N40R2 cells were found to 
be 21-fold resistant to Nutlin-3 and 27-fold resistant to 
MI-63. N_M5R1 and N_N20R1 cells were approximately 
10-fold resistant to both antagonists (Figure 1B and 1C). 
Similar levels of resistance were observed by clonogenic 
cell survival assay (Figure 1D).
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MDMX expression
Levels of MDMX protein were examined as a 
potential explanation for the observed resistance. In the 
NGP derived resistant lines MDMX expression was found 
to be comparable with the level observed in parental NGP 
cells (Figure 2A). MDMX expression was not detectable 
in the SJSA-1 cell line or its resistant derivatives (data not 
shown).
Figure 1: Selection of MDM2 inhibitor resistant clones. SJSA-1 and NGP cell lines with resistance to MDM2/p53 binding 
antagonists were selected following 90 days exposure to either Nutlin-3 or MI-63 at the indicated concentrations A. GI
50
 doses of MI63 
and Nutlin-3 for growth inhibition of parental and resistant SJSA-1 and NGP cell lines, together with the fold-differences in GI
50
 between 
resistant and parental cell lines B. Resistance was confirmed by GI
50
 (n≥3 ± SEM) determination following 72 hours of continuous exposure 
C. and by clonogenic survival following 48 hours of exposure D.
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P-glycoprotein (P-gp) and MRP-1 ABC 
transporter expression
As the development of resistance to 
chemotherapeutic agents is often associated with increased 
expression of the ABC transporters P-gp and MRP-
1 [11] the level of P-gp and MRP-1 protein expression 
in the NGP and SJSA-1 derived cell lines with acquired 
resistance to MDM2/p53 binding antagonists was also 
determined. There was little evidence of P-gp protein 
expression in either the parental or resistance cell lines 
by western blotting and although low levels of MRP-1 
Figure 2: Investigating potential markers of resistance to MDM2-p53 binding antagonists. Levels of MDMX protein 
(independent repeats 1 & 2) were determined by western blotting A. and levels of P-gp and MRP-1 protein by western blotting B. p53, 
ser-15 p53, MDM2 and p21WAF1 protein expression in parental and resistant SJSA-1 and NGP cell lines was compared by western blotting 
following 6 hours of exposure to Nutlin-3 (5 μM) or MI-63 (5 μM) C. and either 2 hours (SJSA-1) or 4 hours (NGP) following 6.3 Gy 
irradiation D. 1% DMSO was used as a vehicle only control.
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protein were observed by western blotting in all of the 
NGP derived resistant cell lines, these levels were similar 
to those observed in parental NGP cells (Figure 2B). P-gp 
and MRP-1 expression was also examined in the NGP 
derived cell lines by flow cytometry and a small sub-
population of resistant cells with higher levels of P-gp and 
MRP-1 than parental NGP cells was evident. However 
the median signal intensity was considerably less than 
the positive control MDCKII-MDR-1 (P-gp) and A549 
(MRP) overexpressing cell lines (Supplementary Figure 
S2), consistent with the lack of significant difference seen 
on Western blot analysis.
Nutlin-3 resistance and DNA damage
In spite of the non-genotoxic mechanism of action 
attributed to Nutlin-3 by Vassilev et al, (2004), recent 
reports have suggested that Nutlin-3 may induce double 
strand breaks [21]. In which case, a potential mechanism of 
resistance may be enhanced DNA-repair activity or tolerance 
to genotoxic lesions [22]. To rule this out, we tested inhibitors 
of DNA-repair enzymes, DNA-PK and PARP-1, which have 
been shown to increase sensitivity to DNA damaging agents 
and could possibly reverse the resistant phenotype [23, 24]. 
There was no significant difference in sensitivity to single 
agent DNA-PK inhibitor (NU7441) or PARP-1 inhibitor 
(Rucaparib) between the parental and Nutlin-3 resistant 
daughter cell lines (Figure 3A). Furthermore, the presence 
or absence of NU7441 or Rucaparib did not impact Nutlin-3 
mediated growth inhibition of the parental or the Nutlin-3 
resistant daughter cell lines (Figure 3B).
Kinetics of γ-H2AX staining after Nutlin-3 
treatment
Immunofluorescence detection of γ-H2AX 
(Phospho-Ser139 histone H2AX) foci is an established 
marker of DNA double strand breaks. These foci can 
be detected within 30min of exposure to a relatively 
low dose of IR (<GI50 dose) (Figure 3C). However, 
γ-H2AX staining was not detected for ≤ 8 hours following 
treatment with up to three times the GI50 dose of Nutlin-3. 
Interestingly, focal and pan-nuclear γ-H2AX staining were 
observed 24 hours after treatment with Nutlin-3. However, 
this timing suggests that γ-H2AX staining following 
Nutlin-3 treatment only occurs much later and could be 
attributed to nucleolytic activity as a result of apoptosis 
and not through direct DNA damage by Nutlin-3. Data 
from another cell line (MCF-7) showed no significant 
dose-dependent increase in the integrated density of 
γ-H2AX immunofluorescent signals in response to 30 min 
treatment with Nutlin-3 (Supplementary Figure S3).
Loss of p53 activation in resistant lines
The activation of p53 by MDM2/p53 binding 
antagonists is characterised by increased levels of p53 protein 
and transcriptional targets such as p21WAF1 and MDM2. To 
determine whether p53 is activated by Nutlin-3 and MI-
63 in the resistant cell lines, western blotting was used to 
compare the levels of p53, p21WAF1 and MDM2 protein 
following exposure to the antagonists. The phosphorylation 
of p53 on serine 15 is considered to be a marker of genotoxic 
stress [25]. Although the original description of the Nutlins 
reported an absence of p53ser15 phosphorylation as 
evidence for non-genotoxicity [6], it is consistently observed 
in response to both Nutlin-3 and MI-63 [26].
Consistent with the activation of p53, the levels 
of total p53 protein, p21WAF1 and MDM2 increased in 
both parental SJSA-1 and NGP wild-type p53 cell lines. 
Phosphorylation of p53 on serine 15 was also detected on 
treatment with the MDM2 inhibitors in both parental cell 
lines (Figure 2C).
Interesting differences between the accumulation 
and phosphorylation of p53 protein in the SJSA-1 and 
NGP derived resistant cell lines were observed. In the 
SJSA-1 derived resistant lines, increases in p53 protein 
were only observed in S_M6R1 cells and were much 
lower than that observed in parental SJSA-1 cells. Nutlin-3 
induced p53 protein stabilisation was notably attenuated 
in the S_M6R1 and S_N40R2 cells. No Phosphorylation 
of p53ser15 was observed in either S_M6R1 cells or S_
N40R2 cells. In contrast, increased baseline levels of p53 
protein were evident in both of the NGP derived resistant 
lines, but these did not increase markedly in response 
to treatment with Nutlin-3 or MI-63 in comparison to 
the increases observed with the parental NGP cells. 
Phosphorylated p53 was also observed in both Nutlin-3 
and MI63 treated N_N20R1 cells and to a lesser extent 
in N_M5R1 cells, but not to the same extent as seen 
with the parental NGP cells. Despite these differences, 
Nutlin-3 and MI63 failed to functionally activate p53 in 
the resistant lines, since no increases in the expression of 
p53 target genes MDM2 and p21WAF1 were observed in 
either S_M6R1 and S_N40R2, or N_M5R1 and N_N20R1 
cells in response to either antagonist (Figure 2C).
Loss of p53 activation in response to genotoxic 
stress
Next, the phosphorylation of p53 on serine 15 
and the levels of p53, MDM2 and p21WAF1 protein were 
compared following X-irradiation in the parental and 
resistant lines to determine whether p53 is activated 
by genotoxic stress. The levels of both total and 
phosphorylated p53 protein increased in response to 
6.3Gy of X-irradiation in the parental cells lines, and 
was transcriptionally active, as shown by increases in 
the expression of p53 target genes MDM2 and p21WAF1 
(Figure 2D). In both NGP derived lines and S_M6R1 
cells p53 protein levels also increased in response to 
irradiation, but to a lesser extent than seen in the parental 
cell lines. Despite these increases, no changes in MDM2 
Oncotarget46208www.impactjournals.com/oncotarget
and p21WAF1protein levels were observed in any of the 
resistant lines. In this regard, the response of the resistant 
lines to irradiation was similar to that of p53 deficient 
HCT116 cells (Supplementary Figure S4). Interestingly, 
phosphorylation of p53 on serine 15 was observed in 
response to X-irradiation in both N_M5R1 and N_N20R1 
cells and in S_M6R1 cells following irradiation, and 
hence in this respect the response of these lines to the 
MDM2/p53 binding antagonists and to genotoxic stress 
differed. Together these results suggest that although 
p53 accumulation is observed, there is no evidence of 
p53-dependent transcriptional transactivation by either 
Nutlin-3 and MI-63 or ionizing radiation in any of the 
Figure 3: Inhibition of DNA-PK and PARP-1 do not influence the sensitivity of either the parental or their resistant 
counterparts to Nutlin-3. The growth inhibitory GI50 values for single agent NU7441/Rucaparib A., or Nutlin-3 ± NU7441/Rucaparib 
B. in NGP and SJSA-1 cell lines and their most Nutlin-3 resistant counterparts (bars without an error indicate that the GI50 dose was >10). 
Confocal images of γ-H2AX immunofluorescent staining in SJSA-1 and NGP cell lines following treatment with 5μM Nutlin-3 (~ 3x and 2x 
GI50 respectively) C.
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cell lines selected for resistance to MDM2/p53 binding 
antagonists.
DNA sequence and TP53 FISH analysis
Mutations in the DNA binding domain of p53 occur 
in ~ 50% of tumours and have been reported in cells 
selected for resistance to Nutlin-3 [19, 20]. To determine 
whether p53 mutations are present in the SJSA-1 and 
NGP derived cell lines with resistance to both MI-63 and 
Nutlin-3 described here, exons 4 to 9 of p53, which encode 
the DNA binding domain, were sequenced. Parental SJSA-
1 and NGP cells were found to have wild-type p53 as 
previously reported [27, 28]. Point missense mutations 
resulting in amino acid substitutions were detected in all of 
the resistant cell lines (Figure 4A and 4B). A homozygous 
G>A transition resulting in a Glu285Lys mutation was 
found in both the S_N40R2 and S_M6R1 resistant cell 
lines derived from SJSA-1, whilst a heterozygous C>A 
transversion resulting in a Pro152Thr mutation was 
detected in both of the NGP derived cell lines. The NGP 
derived lines were also found to have additional point 
mutations; A G>T transversion resulting in a Cys176Phe 
heterozygous mutation was detected in the N_M5R1 
cells whilst a C>A transversion resulting in a Pro98His 
mutation was found in the N_N20R1 cells.
Loss of heterozygosity is commonly observed in 
conjunction with p53 mutations and would account for 
the homozygous mutation observed in the SJSA-1 derived 
cell lines. This was investigated further with fluorescent 
in situ hybridisation (FISH) (Figure 4C and Table 1). The 
parental SJSA-1 and NGP cell lines were confirmed to 
have two TP53 alleles (94% and 95% respectively), as 
were the NGP-derived N_N20R1 (93%) and N_M5R1 
(92%) cells. The loss of one TP53 copy was evident 
in the S-N40R2 cell line, with 68% of cells containing 
a single copy of TP53, and a further 14% having lost 
both copies. Whilst the majority of S_M6R1 cells had 
two copies of TP53 (77%), a single copy was observed 
in 20% of the population (Table 1). The predominant 
presence of two copies of TP53 in the S_M6R1 cell line 
and the clear evidence of a homozygous mutation in 
the sequence analysis (Figure 4A) indicates uniparental 
disomy, in which a deletion of a normal TP53 allele has 
been accompanied by a duplication of the mutated allele.
TP53 mutations occur in response to genotoxic 
stress. Despite being believed to activate p53 by a non-
genotoxic mechanism, both Nutlin-3 and MI-63 were 
found to induce phosphorylation of p53 on serine 15, a 
known marker of genotoxic stress (Figure 2C). To establish 
whether DNA damage is implicated in the phosphorylation 
of p53 on serine 15 observed in response to Nutlin-3 and 
MI63, the dependence of this phosphorylation on the 
DNA damage dependent ATM and DNA-PK kinases was 
assessed.
The p53 ser15 phosphorylation occurred less rapidly 
in response to Nutlin-3 and MI-63 than in response to 
X-irradiation (Supplementary Figure S5A). The SJSA-
1 cells were then pre-treated with the ATM specific 
inhibitor KU55933 [29] and either exposed to Nutlin-3 
or MI-63, using X-irradiation as a positive control 
(Supplementary Figure S5B). As expected, KU55933 
was observed to reduce p53 serine 15 phosphorylation 
following irradiation. However, serine 15 phosphorylation 
induced by the MDM2/p53 antagonists was not effected 
by KU55933. Specific inhibitors of the DNA damage 
activated kinase DNA-PK, KU-0060648 and NU7441 
[30], were also found to have little effect on Nutlin-3 
and MI-63 induced phosphorylation of p53 on serine-15 
(Supplementary Figure S5B). Together, these results show 
that neither Nutlin-3 nor MI-63 are inducing DNA damage 
and therefore these agents themselves are not responsible 
for the p53 mutations observed in the selected resistant 
cell lines.
Next, mutation specific PCR was used to investigate 
whether Nutlin-3 and MI63 treatment had selected for pre-
existing mutations which might be present at a low level 
in the parental cell populations. Mutation specific PCR 
is more sensitive than sequencing by PCR based Sanger 
dideoxy chain termination and has been previously shown 
in this laboratory to detect mutations present in 0.05% of 
the population [3]. Consistent with the sequencing results, 
there was no evidence of wild-type p53 in either the S_
M6R1 or the S_N40R2 cell lines and a PCR product was 
obtained with primers specific to the codon 285 mutation 
in both of these cell lines (Figure 4D). Similarly the 
presence of mutations in codons 98, 152 and 176 were 
confirmed in N_M5R1 and N_N20R1 cells as predicted by 
sequencing (Figure 4D). Low levels of PCR product was 
detected in SJSA-1 parental cells using the mutant codon 
285 primers and in NGP parental cells using the mutant 
152 primers and 98 primers.
Downstream cellular effects on growth and 
apoptosis
Next, comparisons between changes in cell cycle 
distribution and the level of apoptosis observed in the 
parental cell lines and their resistant counterparts were 
made following exposure to the MDM2-p53 binding 
antagonists. Both p53-dependent cell cycle arrest and 
apoptosis are well characterised responses to MDM2/p53 
binding antagonists that occur following the activation of 
p53 by these agents and result in growth inhibition and 
anti-tumour activity.
In response to 24 hours of exposure to the 
antagonists, SJSA-1 parental cells were observed to 
accumulate in G2/M phase. The S-phase fraction of MI-
63 treated cells was similar to that observed in untreated 
cells and potentially reflects an S-phase arrested sub-
population. The percentage of cells with sub-G1 DNA 
content increased in response to both antagonists (data not 
shown). In contrast, Nutlin-3 and MI-63 had little effect 
on the cell cycle distribution or the induction of apoptosis 
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in the resistant S_M6R1 and S_N40R2 cell lines (Figure 
5A).
Nutlin-3 and MI-63 were similarly found to induce 
cell cycle arrest in parental NGP cells, whilst having 
little effect on the NGP derived N_M5R1 and N_N20R1 
cells. An increase in both G1 and G2/M phase cells and 
a corresponding decrease in S phase cells was observed 
in NGP cells in response to both MDM2-p53 binding 
antagonists, whereas smaller changes in cell cycle 
distribution were evident in the resistant lines (Figure 5A). 
Interestingly, with the SJSA-1 cells there is predominantly 
a G2 arrest, but with the NGP cells both G1 and G2 
increases are seen.
Figure 4: The MDM2 inhibitor resistant sub-clones are TP53 mutant and detectable in the parental population. 
Chromatograms showing TP53 mutations in resistant cell lines at both stages of selection in SJSA-1 A. and NGP B. derived lines. 
Representative FISH images showing TP53 copies (red) in parental and resistant cell lines together with centromeric chromosome 17 
(green) signals using a dual probe against p53 and chromosome 17 centromeric DNA C. Mutation specific PCR detecting the presence of 
low frequency mutations in parental SJSA-1 (A) and NGP (B) cell cultures. Primers specific to the identified mutations in codons 285, 98, 
152 and 176 were used as indicated, and the codon 285 mutation in parental SJSA-1 cells was visualized by inverting the image for clarity D.
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Apoptosis was also induced by the MDM2-p53 
binding antagonists in the parental cell lines. Following 
48 hours of exposure, the caspase-3/7 activity increased 
in response to both of the antagonists in a dose-dependent 
manner (Figure 5B). In contrast, by comparison there was 
little evidence of the resistant lines undergoing apoptosis 
following 48 hours of exposure to MI-63 or Nutlin-3. 
Increases in caspase-3/7 activity were not observed in S_
M6R1, S_N40R2 and N_M5R1 cells, whilst in N_N20R1 
cells were only observed following exposure to 40 μM 
Nutlin-3, a high dose at which off-target p53-independent 
side effects start to be seen.
The inability of Nutlin-3 and MI-63 to induce either 
cell cycle arrest or cytotoxicity in the resistant cell lines is 
consistent with their inability to activate p53-dependent 
transcription in these cells.
Downstream cellular responses to ionizing 
radiation
To investigate the response of the cell lines with 
acquired resistance to MDM2/p53 binding antagonists 
to conventional therapy we assessed their response to 
DNA damage in the form of X-radiation. The results 
showed there was no difference between the parental and 
resistant cell lines in their clonogenic survival following 
X-irradiation. Similarly there was no difference in the 
clonogenic cell survival response to X-irradiation between 
the HCT116 p53 +/+ and p53 -/- isogenic cell line pair 
(Figure 6A). The response to X-irradiation of the sensitive 
and their MDM2 inhibitor resistant daughters was 
unaffected in short term growth inhibition assays (Figures 
6B, 6C and 6D). This is consistent with the genomics of 
drug sensitivity data made available by the Wellcome 
Trust Sanger Institute (Figure 6E and 6F). These data 
show that the genetic status of TP53 is the most significant 
determinant of growth inhibitory response to Nutlin-
3a (The active enantiomer of Nutlin-3 racemic mixture) 
(Figure 6E). Conversely, TP53 genetic status is not flagged 
up as a determinant of growth inhibitory response to any 
of the genotoxic agents used in their panel of compounds 
(e.g. Doxorubicin) (Figure 6F). These observations overall 
strongly support the notion that MDM2 inhibitors result in 
selection of TP53 mutant clones and that these clones are 
still likely to remain sensitive to DNA damaging agents.
DISCUSSION
MDM2/p53 binding antagonists have been 
demonstrated to have anti-tumour activity in in vivo 
xenograft models [6, 8], and their clinical potential for 
the treatment of p53 wild-type tumour types has been 
confirmed by initial results from phase I clinical trials 
that have focused on leukaemia and sarcoma, which are 
predominantly p53 wild-type at diagnosis and are MDM2-
amplified or have high expression of MDM2 [9]. However, 
the development of resistance to these agents is likely to 
Table 1: Cell lines and their TP53 genetic and cytogenetic status
Cell Line Exon Codon Mutation Amino Acid Substitution 17p status
SJSA-1 - - - - 2R2G: 99/106 (94%) 1R2G: 5/106 (4.7%)
S-M6R1 Exon 8 285 GAG→AAG 
(homozygous)
Glu → Lys
2R2G: 102/133 (77%) 1R2G: 
17/133 (13 %) 2R4G: 9/133 (6.8%)
S-N40R2 Exon 8 285 GAG→AAG 
(homozygous)
Glu → Lys
2R2G: 6/100 (6%) 1R2G: 68/100 
(68%) 1R3G: 6/100 (6%) 0R2G: 
14/100 (14%)
NGP - - - - 2R2G: 97/102 (95%)
N-N20R1 Exon 4
Exon 5
98
152
CCT→CAT 
(heterozygous)
CCG→ACG 
(heterozygous)
Pro→His
Pro→Thr
2R2G: 102/110 (93%)
1R2G:7/110 (6.4%)
N-M5R1 Exon 5
Exon 5
152
176
CCG→ACG
(heterozygous)
TGC→TTC
(heterozygous)
Pro→Thr
Cys→Phe
2R2G:106/116 (92%)
1R2G:7/116 (6.4%)
Details of TP53 mutations and chromosome 17p status established by FISH in cell lines selected for resistance to 
MDM2-p53 binding antagonists. R (Red), G (Green) refer to the number and percentage of 17p (TP53) and centromeric 
signals respectively.
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influence their effectiveness in the clinic and knowledge 
of them is required to inform follow-up strategies. In this 
study, the mechanism through which resistance to these 
antagonists might develop in cells with amplification and 
overexpression of MDM2 has been investigated in detail 
with two chemically different binding antagonists, MI-63 
and Nutlin-3.
MDM2-amplification and TP53 mutation are 
widely and consistently reported as mutually exclusive, 
so that the selection for TP53 mutation in the context of 
MDM2 amplification represents a novel genotype that 
may occur in therapeutic situations, particularly with 
those cancers in which MDM2-amplification is prevalent, 
such as sarcomas, against which MDM2 inhibitors have 
Figure 5: Downstream effects on cell cycle progression and apoptosis. The effects of Nutlin-3 (5 μM) and MI-63 (5 μM) on cell 
cycle distribution in parental and resistant SJSA-1 and NGP cell lines determined by flow cytometry following 24 hours of exposure (n=2 ± 
SEM) A. Caspase 3/7 Glo assays showing the level of caspase 3 and 7 activation by Nutlin-3 and MI-63 in SJSA-1 and NGP parental and 
resistant cell lines following 48 hours of exposure B.
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demonstrated activity in clinical trials. Hence the need 
to investigate selected resistant cells with this unusual 
genotype. This has clear clinical relevance for what 
potential combination or follow on treatment options 
might be appropriate and provides a mechanistic rationale. 
This has not been previously investigated. Resistant cell 
lines were developed from two p53 wild-type, MDM2-
amplified cell lines of different tumour types, with S_
M6R1 and S_N40R2 cells originating from the SJSA-1 
osteosarcoma cell line, and N_M5R1 and N_N20R1 cells 
from the NGP neuroblastoma cell line [27, 31]. Following 
selection these cell lines were found to be resistant to 
Figure 6: MDM2-p53 binding antagonist resistant daughter cells retain their sensitivity to ionizing radiation 
irrespective of their p53 status. Clonogenic survival curves of MDM2 inhibitor sensitive parental and resistant daughter cell line 
pairs along with HCT116p53+/+ & -/- isogenic paired cell lines, in response to ionizing radiation A. Percentage confluence of the two 
otherwise isogenic MDM2 sensitive and resistant cell line pairs B. and C. and HCT116p53+/+ & -/- isogenic cell line pair D. over time 
using Incucyte; in response to 0 or 4Gy ionizing radiation. Volcano plots show the effect that common genetic alterations in cancer have on 
cell line sensitivity to Nutlin-3a E., and the effect that TP53 mutations have on sensitivity of a large panel of genotoxic and non-genotoxic 
anticancer compounds F. For further explanation of the volcano plot please see http://www.cancerrxgene.org.
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both MI-63 and Nutlin-3 as well as the isoindolinones, 
a chemically distinct class of MDM2/p53 binding 
antagonists being developed in this laboratory [32].
Slight increases in both P-gp and MRP-1 protein 
expression was detected in all of the NGP derived cell 
lines by flow cytometry. Nutlin-3 is a known substrate 
of P-gp [18] and whilst the susceptibility of MI-63 to 
transport mediated resistance is unknown, these results 
suggest that MI-63 is also a substrate of both P-gp and 
MRP-1. However, as the increases observed were an 
order of magnitude lower than those observed in the 
positive control MDCKII and A549 cells, increases in 
the expression of drug efflux pumps following long term 
exposure to Nutlin-3 or MI-63 are unlikely to account for 
their resistance to these agents.
There was no significant difference in sensitivity to 
the DNA repair enzyme inhibitors NU7441 and Rucaparib 
as single agents, between the parental cell lines and their 
resistant counterparts. This strongly suggests that there 
is no difference in DNA repair processes or elevated 
tolerance to DNA damage between the parental and 
resistant cell line pairs. Interestingly, NGP and N_N20R1 
cells were found to be sensitive to single agent Rucaparib, 
which suggests that both the parental NGP cells and 
their resistant clones may have a low homologous 
recombination (HR) DNA repair capacity [33]. However, 
this reduced HR capacity in the NGP cells does not make 
them more sensitive to MDM2 inhibitors than the SJSA-1 
cells.
Concomitant treatment with Nutlin-3 ± NU7741/
Rucaparib did not influence the growth inhibitory 
sensitivity to Nutlin-3 of neither NGP and N_N20R1 nor 
SJSA-1 and S_N40R2 cell line pairs. These data, along 
with the absence of γ-H2AX staining for up to 8 hours 
of treatment with Nutlin-3, are consistent with the non-
genotoxic mechanism of action of Nutlin-3 (Figure 3).
In comparison to the increases in MDM2 and 
p21WAF1 expression observed in the parental lines, there 
was no evidence of p53 dependent transactivation being 
induced by either MDM2-p53 binding antagonists 
or ionizing radiation in any of the resistant cell lines. 
Furthermore, the cell cycle arrest and apoptosis observed 
in response to Nutlin-3 and MI-63 in both parental cell 
lines was not observed in either the SJSA-1 derived lines 
or the NGP derived cell lines. Mutations within the DNA 
binding domain of p53 were subsequently identified 
accounting for the demonstrated abrogation of p53 
function. TP53 mutations were found in codon 285 in 
the SJSA-1 resistant lines and codons 98, 152 and 176 
in the NGP derived lines. Whilst these residues are not 
one of the 6 residues considered to be ‘hotspots’ [34], 
mutations in codons 152, 176 and 285 occur frequently 
in multiple tumour types. Codon 98 mutations have been 
documented less frequently [35] although, P98H has been 
reported by the IARC TP53 mutation database to result 
in inactive p53.
Intra-tumour heterogeneity for p53 status has been 
demonstrated in a number of different tumour types, 
and the identical nature of the mutation identified in 
both SJSA-1 derived lines, and of one of the three p53 
mutations found in NGP derived lines demonstrated 
here, suggests that these were present in the original 
populations at low frequencies and were selected for 
during the course of treatment. Whilst these results are 
in contrast with previous studies which found Nutlin-3 
to be inducing p53 mutations [19, 20], the generation of 
identical mutations by two chemically distinct binding 
antagonists on multiple occasions is unlikely and as a class 
of agents, MDM2/p53 binding antagonists are considered 
to be non-genotoxic reactivators of wild-type p53 [6]. 
The phosphorylation of p53 ser15 by Nutlin-3 and MI-63 
observed here was independent of both ATM and DNA-
PK, consistent with these antagonists acting through DNA 
damage independent mechanisms. Furthermore, the results 
presented here support the findings of Jones et al., who 
identified identical p53 mutations in H929 cells selected 
independently for resistance against Nutlin-3 and MI-63 
[36]. All but one of the mutant alleles was detected in 
the parental cell populations by mutation-specific PCR, 
indicating that the binding antagonists had selected for 
existing p53 mutations present in the parental populations. 
However, we cannot rule out that the codon 176 mutation 
in the N_M5R1 cell line was present below the level of 
detection by mutation specific PCR in the parental cell 
population, or was a de novo mutation occurring during 
the selection procedure.
The demonstration that long term exposure to low 
concentrations of MDM2-p53 antagonists appears to 
select for p53 mutations which might be present at low 
levels in parental populations is of direct therapeutic 
relevance. The selection of p53 mutant populations 
occurred in response to two chemically distinct classes 
of binding antagonists with two different cell lines and 
therefore identified a common mechanism by which 
resistance to this class of agent will develop. These 
mutations are likely to have occurred spontaneously 
in the parental populations, and then been selected for 
following p53 activation and the growth inhibition or 
apoptosis of cells expressing wild-type p53. Whilst NGP 
cells were derived from a patient who had received prior 
chemotherapy, SJSA-1 cells originated from a patient 
having had received no prior treatment and hence these 
mutations are unlikely to have originated during prior 
treatment. If the selection for TP53 mutant sub-clones 
was reflected in a therapeutic setting, it would suggest 
that patients with resistance to MDM2/p53 binding 
antagonists would benefit from follow up treatment with 
agents acting through p53 independent mechanisms. In 
this respect, it is notable that the response of both the 
NGP and SJSA-1 resistant cell lines to ionizing radiation 
was similar to that of parental NGP and SJSA-1 cells. 
This is consistent with information on the Sanger 
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Genomics of Drug Sensitivity database, which shows 
no significant difference in response to a wide range 
of DNA damaging agents for cell lines of wild-type 
compared with mutant p53 status, despite demonstrating 
a very marked difference in response to Nutlin-3 (Figure 
6E and 6F). It is also consistent with p53 dependent 
apoptosis having a relatively modest role in cellular 
response to ionizing radiation, as reviewed by Gudkov 
et al [37].
MDM2-amplification and p53 mutations are 
mutually exclusive events and the otherwise isogenic 
paired cell lines generated here are among the first 
examples of this. The effect of MDM2-amplifications in 
a mutant p53 background is currently unknown and how 
this may affect the efficacy of current chemotherapeutic 
agents is an important consideration for treating patients 
following MDM2/p53 binding antagonist therapy. 
These results presented here suggest these patients will 
remain responsive to conventional therapy. Derived 
resistant cell lines remained responsive to X-irradiation 
and classical multi-drug resistance is unlikely to be 
a consideration for these patients, as P-gp and MRP-
1 expression remained low during the development of 
resistance. The paired cell lines generated here provide 
the opportunity to investigate this in greater detail, as 
well as being a valuable resource for testing the cellular 
specificity of novel MDM2-p53 binding antagonists.
MATERIALS AND METHODS
Reagents
Nutlin-3 (Immunodiagnostic Systems Ltd) and MI-
63 (synthesised by Siena Biotech S.p.A) were stored as 
stock solutions in DMSO at -20°C and diluted in culture 
medium immediately prior to use. KU55933 [29] and KU-
0060648 [38] were provided by Kudos Pharmaceuticals, 
and NU7441 [30] was developed in this laboratory. 
Rucaparib (AG-014699) was kindly provided by Prof. 
Nicola J. Curtin.
Cell culture and generation of resistant cell lines
Resistant cell lines were established by exposing 
NGP and SJSA-1 cells to Nutlin-3 or MI-63. Single cell 
derived colonies were isolated with cloning cylinders 
and the clonal population expanded in culture medium 
containing the MDM2/p53 antagonist refreshed weekly 
for 60 days. Stage 1 resistant clones were then further 
exposed to increased concentrations of Nutlin-3 or 
MI-63 for 30 days to generate stage 2 resistant clones 
(Figure 1A). NGP and SJSA-1 parental cell lines and 
resistant clones were sub-cultured weekly, and were not 
used beyond 30 passages post authentication by short 
tandem repeat (STR) profiling (LGC Standards).
Cell growth inhibition assays
GI
50
 (50% growth inhibitory concentration) values 
were determined by the sulforhodamine B (SRB) staining 
method [39]. Cells were seeded in 96-well plates (SJSA-
1; 2×103 cells/well, NGP; 5×103 cells/well) and allowed 
to attach for 24 hours before exposure to Nutlin-3 or 
MI-63 for 72 hours. Nutlin-3 and NU7441/Rucaparib 
were administered concomitantly. Cells were fixed in 
Trichloroacetic Acid (10% v/v), stained with SRB (0.4% 
w/v) and the absorbance measured at 570 nM using a 
SpectroMax 250 (Molecular Devices, Berkshire, UK) 
microwell plate scanner. GI
50
 values were calculated using 
GraphPad PRISM software (GraphPad Software, Inc., 
San Diego, CA, USA) and fold-resistance determined. 
For assessment of cell confluence and proliferation over 
time, cells were seeded 24 hours before treatment and 
confluence was measured by IncuCyte® Zoom (Essen 
BioSciece) every 6 hours.
Western blotting
Western blotting was performed as previously 
described [2] using primary antibodies raised against 
P-glycoprotein (1:100, sc-13131: Santa Cruz Biotech, 
CA, USA), MRP-1 (1:200, sc-18835, Santa Cruz Biotech), 
MDM2 (1:100, IF2; EMD Chemicals Inc., Gibbstown, 
NJ, USA), p53 (1:300, DO-7; Novocastra Laboratories, 
Newcastle, UK), serine 15 pp53 (1:1000, # 9284; Cell 
Signalling, Danvers, MA, USA) and p21WAF1 (1:100, 
EA10, EMD Chemicals Inc). α-Tubulin (DM1A; Sigma-
Aldrich, Dorset, UK) was used as a marker of protein 
loading.
Flow cytometry for P-gp and MRP-1
Harvested cell samples were pre-incubated with 
block solution (phosphate buffered saline (PBS) + 10% 
Foetal Bovine Serum) for 12-16 hours, washed twice with 
cold PBS and incubated for 30 minutes at 4 °C with either 
FITC anti-P-gp (17F9) or isotype-matched FITC Mouse 
IgG2a control (BD Bioscience, Oxford, UK). Intracellular 
staining with FITC anti-MRP1 (QCRL-3) was carried out 
using the Intra-stain Fix/Perm kit (Becton Dickinson). 
Analysis of fluorescence staining was performed with a 
FACScan flow cytometer using CELLQuest Software 
(Becton Dickinson).
Flow cytometry for cell cycle analysis
Cells were harvested and fixed in ethanol (70 % v/v) 
and PBS (30% v/v) at -20°C, then stored in 4°C for at 
least 2 hours. Fixed cells were rehydrated, stained with 
propidium iodide (40μg/ml) and RNase (10μg/ml) and 
analysed for DNA content (FACScan flow cytometer, BD 
Bioscience, Oxford, UK). 10,000 cells were counted for 
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each sample and analysed using WinMDI 2.8 software 
(Joe Trotter, Scripps Institute, free download).
Caspase –Glo 3/7 assays
Caspase 3/7 activity was determined using a 
Caspase-Glo ® 3/7 Assay Kit (Promega UK Ltd., 
Southampton, UK) as a measure of apoptosis. Cells were 
seeded in 96 well plates, and were tested according to 
the manufacturer’s instructions. Following 48 hours of 
exposure to Nutlin-3 or MI-63, a 1:1 volume of Caspase-
Glo 3/7 reagent was added to the wells for 1h, the well 
contents transferred to a white opaque plate and then 
analysed using a microplate luminometer (Berthold 
Technologies, Herefordshire, UK).
p53 Sequencing and mutation specific PCR
Total DNA was extracted using a DNeasy Blood 
& Tissue Kit (QIAGEN Inc., UK) and PCR used to 
amplify exons 4-9 of TP53. PCR products were purified 
using a QIAquick PCR purification kit (QIAGEN Inc., 
UK) and sequenced by PCR based Sanger dideoxy chain 
termination. Mutations detected by sequencing were 
then investigated by mutation specific PCR. Primer pairs 
specific to either wild-type or mutant TP53 were designed 
as follows:
codon 98: sense wild-type 5′-GCCCCTGTCATCTT 
CTGTCCC -3′,
 sense mutant 5′- GCCCCTGTCATCTTCTGTC 
CA- 3′,
 anti-sense 5′-ATACGGCCAGGCATTGAAGT -3′;
codon 152: sense wild-type 5′-GGTTGATTCCACA 
CCCC-3′,
 sense mutant 5′-GGTTGATTCCACACCCA-3′,
 anti-sense 5′-GGGCCAGACCTAAGAGCAAT-3′;
codon 176: sense wild-type 5′-GGAGGTTGTGA 
GGCGCTG-3′,
 sense mutant 5′-GGAGGTTGTGAGGCGCTT-3′
 anti-sense GGAGGGCCACTGACAACCA
codon 285: sense wild-type 5′- GGAGAGACCG 
GCGCACAG-3′
 sense mutant 5′- GGAGAGACCGGCGCACAA -3
 anti-sense 5′- TCCACTGATAAGAGGTCCC-3′
Following PCR, products were run on 2% agarose 
gels containing Ethidium Bromide and were visualised by 
UV light (Biorad imaging system).
Fluorescence in situ hybridisation (FISH)
Cells were washed with PBS, fixed in 3:1 Methanol: 
Acetic Acid, and FISH preformed using a p53 (17p13) 
(spectrum red)/Chromosome 17 centromeric (spectrum 
green) probe (Kreatech Diagnostics, Amsterdam, Holland) 
according to the manufacturer’s instructions. Results 
were analysed by fluorescence microscopy with two 
independent assessors, and a total of 100 interphase cells 
were scored. The percentage of cells with each differing 
number of red and green signals was determined and a 5% 
cut off applied to remove false positives. Cells containing 
either 1 red and 2 green signals, or 0 red and 2 green 
signals, were considered to have lost either one or both 
p53 alleles respectively.
Immunofluorescence detection of γ-H2AX 
staining
Immunofluorescence detection of γ-H2AX was 
carried out as described in [40] apart from changes to the 
drug treatment schedule.
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